SYH2051

PreclinicalSmall molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

SYH2051 is one of 61 small molecule programs targeting Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Colorectal CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Halaven

Eisai

Preclinical

38 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

Megace

Bristol-Myers Squibb

Preclinical

4 6

Voltaren

Novartis

Preclinical

1 7

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 8

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 9

Spravato

WWim Janssens

Preclinical

2 10

Chirocaine

PPurdue Pharma LP

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Not yet recruiting

Breast Cancer

NCT06775236

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 1/2·NCT06775236·410 enrolled

Locally Advanced Head and Neck Cancer1 trial

A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT06011291·73 enrolled

Colorectal Cancer1 trial

A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors

Active, not recruiting·FFujian Cancer Hospital·N/A·NCT07104877·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SYH2051. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SYH2051 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SYH2051. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

SYH2051

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Breast Cancer1 trial

Locally Advanced Head and Neck Cancer1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News